355 related articles for article (PubMed ID: 14671247)
21. Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial.
Arima H; Anderson C; Omae T; Liu L; Tzourio C; Woodward M; Macmahon S; Neal B; Rodgers A; Chalmers J;
J Hypertens; 2010 Feb; 28(2):395-400. PubMed ID: 19864958
[TBL] [Abstract][Full Text] [Related]
22. Incidence of recurrent stroke in primary care during preventive treatment based on perindopril with or without indapamide.
Padma MV; Kaul S
Neurol India; 2007; 55(2):141-4. PubMed ID: 17558118
[TBL] [Abstract][Full Text] [Related]
23. Trials on blood pressure-lowering and secondary stroke prevention.
Chalmers J
Am J Cardiol; 2003 May; 91(10A):3G-8G. PubMed ID: 12781902
[TBL] [Abstract][Full Text] [Related]
24. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee.
J Hum Hypertens; 1998 Sep; 12(9):627-9. PubMed ID: 9783492
[TBL] [Abstract][Full Text] [Related]
25. [Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases-a large-scale, randomized, placebo controlled trial].
Liu LS; Gong LS; Wang W;
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul; 33(7):613-7. PubMed ID: 16080808
[TBL] [Abstract][Full Text] [Related]
26. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.
Arima H; Tzourio C; Anderson C; Woodward M; Bousser MG; MacMahon S; Neal B; Chalmers J;
Stroke; 2010 Feb; 41(2):394-6. PubMed ID: 20044530
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients.
Chalmers J; Castaigne A; Morgan T; Chastang C
J Hypertens; 2000 Mar; 18(3):327-37. PubMed ID: 10726720
[TBL] [Abstract][Full Text] [Related]
28. Stroke secondary prevention and blood pressure reduction: an observational study of the use of PROGRESS therapy.
Bugnicourt JM; Chillon JM; Canaple S; Lamy C; Godefroy O
Fundam Clin Pharmacol; 2008 Apr; 22(2):217-22. PubMed ID: 18353116
[TBL] [Abstract][Full Text] [Related]
29. [ADVANCE study: objectives, design and current status].
Chalmers J
Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
[TBL] [Abstract][Full Text] [Related]
30. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
Tavakoli M; Pumford N; Woodward M; Doney A; Chalmers J; MacMahon S; Macwalter R
Eur J Health Econ; 2009 Feb; 10(1):111-9. PubMed ID: 18446392
[TBL] [Abstract][Full Text] [Related]
31. The PROGRESS trial three years later: time for a balanced report of effectiveness.
Wennberg R; Zimmermann C
BMJ; 2004 Oct; 329(7472):968-70. PubMed ID: 15499116
[TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease.
Campbell DJ; Neal BC; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Patel A; Macmahon SW; Woodward M
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):413-8. PubMed ID: 17568241
[TBL] [Abstract][Full Text] [Related]
33. You should treat patients over the age of 80 who have hypertension.
Lundberg GD
Medscape J Med; 2008; 10(8):185. PubMed ID: 18924637
[No Abstract] [Full Text] [Related]
34. [Reduced risk of stroke recurrence due to hypotensive medication, irrespective of the initial blood pressure].
Lenders JW; Thien T
Ned Tijdschr Geneeskd; 2002 Mar; 146(9):398-9. PubMed ID: 11901939
[TBL] [Abstract][Full Text] [Related]
35. Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.
Gueyffier F; Subtil F; Bejan-Angoulvant T; Zerbib Y; Baguet JP; Boivin JM; Mercier A; Leftheriotis G; Gagnol JP; Fauvel JP; Giraud C; Bricca G; Maucort-Boulch D; Erpeldinger S;
J Hum Hypertens; 2015 Jan; 29(1):22-7. PubMed ID: 24739801
[TBL] [Abstract][Full Text] [Related]
36. [ADVANCE: a morbidity mortality study of diabetes and hypertension].
Heim A; Feihl F; Waeber B
Rev Med Suisse; 2008 Jan; 4(139):28, 30, 32-3. PubMed ID: 18251212
[TBL] [Abstract][Full Text] [Related]
37. Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key.
Bath P
Stroke; 2003 May; 34(5):1334-5. PubMed ID: 12702833
[No Abstract] [Full Text] [Related]
38. [Efficacy of a converting enzyme inhibitor in the prevention of recurrence of stroke].
Masson C
Presse Med; 2001 Nov; 30(35):1716-7. PubMed ID: 11775593
[No Abstract] [Full Text] [Related]
39. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.
Perkovic V; Ninomiya T; Arima H; Gallagher M; Jardine M; Cass A; Neal B; Macmahon S; Chalmers J
J Am Soc Nephrol; 2007 Oct; 18(10):2766-72. PubMed ID: 17804673
[TBL] [Abstract][Full Text] [Related]
40. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial.
Ninomiya T; Perkovic V; Gallagher M; Jardine M; Cass A; Arima H; Anderson C; Neal B; Woodward M; Omae T; MacMahon S; Chalmers J;
Kidney Int; 2008 Apr; 73(8):963-70. PubMed ID: 18272959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
